Protocol for HRF-HMO vs eHF-HMO in infants with suspected cow's milk allergy

Photo by Visualss / Unsplash

Frontiers in Medicine Published April 25, 2026 Medically reviewed April 25, 2026 Study authors: Boutaina Zemrani, Nicholas P. Hays, Noura Darwish, Kirsten Beyer, Roberto Berni Canani, Hania Szajew… DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note this protocol lacks reported results for HRF-HMO vs eHF-HMO in infants with suspected cow's milk allergy.

This study is a randomized controlled blinded multi-center trial protocol involving 104 healthy full-term formula-fed infants ≤ 8 months of age with physician-diagnosed or suspected cow's milk allergy. The trial is set in Europe. The intervention is a new hydrolyzed rice protein-based formula containing 2-fucosyllactose and lacto-N-neotetraose (HRF-HMO), compared with an extensively hydrolyzed formula containing 2-fucosyllactose and lacto-N-neotetraose (eHF-HMO). The primary outcome is age-appropriate growth, specifically weight-for-age z-score non-inferiority to the control. Secondary outcomes include length, head circumference, bone length, allergy symptoms, gastrointestinal tolerance, health-related quality of life, adverse events, and formula compliance. Follow-up is scheduled monthly until 4 months post-enrollment.

Safety and tolerability data, including adverse events, serious adverse events, discontinuations, and overall tolerability, are not reported in this protocol. Similarly, specific main results regarding growth metrics and other secondary outcomes are not available at this stage. Funding or conflicts of interest are not reported. Limitations specific to the protocol design are not detailed in the provided text.

Because this document is a protocol, no causal conclusions can be drawn regarding the efficacy or safety of HRF-HMO versus eHF-HMO. The practice relevance remains uncertain until the trial results are published. Clinicians should await final data before making recommendations based on this specific intervention.

Study Details

Study typeRct

EvidenceLevel 2

PublishedApr 2026

View Original Abstract ↓

Hydrolyzed rice formulas (HRF) are recommended by expert societies as a suitable option for the management of non-breastfed infants with cow’s milk allergy (CMA). There is a growing trend towards the use of HRF driven by their plant-based source, appealing taste, and established safety and efficacy. Human milk oligosaccharides (HMOs) play a significant role in promoting gut and immune health of infants. There is currently no evidence regarding the growth and safety of infants receiving HRF containing two HMOs. The aim of the RIGHT-GO study is to assess the growth, safety and health-related quality of life of infants receiving a new HRF containing two manufactured HMOs, 2-fucosyllactose (2’FL) and lacto-N-neotetraose (LNnT). RIGHT-GO is a randomized controlled blinded multi-center trial (NCT06633250) conducted in Europe. Healthy full-term formula-fed infants ≤ 8 months of age with physician-diagnosed or suspected CMA will be randomized to receive either the new HRF (HRF-HMO) or an extensively hydrolyzed formula (eHF-HMO) for 4 months. Both formulas contain 1.5 g/L of 2’FL and LNnT (2:1 ratio). The primary objective is to demonstrate that infants with CMA fed the new HRF-HMO have age-appropriate growth that is non-inferior to that of infants with CMA fed a control eHF-HMO. The sample size required to demonstrate non-inferiority in weight-for-age z-score with a non-inferiority margin of −0.5 standard deviation is 104 infants (52 per group). Secondary outcomes include other growth parameters (length, head circumference, bone length), allergy symptoms, gastrointestinal tolerance, health-related quality of life, as well as adverse events and formula compliance. Assessments will take place at enrollment, then monthly until 4 months post-enrollment. The RIGHT-GO study will provide strong evidence on the growth, safety and gastrointestinal tolerance of the new HRF-HMO in infants with physician-diagnosed or suspected CMA. The results will be presented at scientific meetings and published in international peer-reviewed journals. https://clinicaltrials.gov/study/NCT06633250, Identifier: NCT06633250.